Diagnosis and Drug Treatment of Alzheimer’s Disease in China is Low and Will Remain Low Through 2012
world’s leading research and advisory firms focusing on pharmaceutical and
healthcare issues, finds that the diagnosis and drug treatment of Alzheimer’s
particularly in rural regions. Although rural cases of Alzheimer’s disease
will account for approximately 70 percent of the prevalent Alzheimer’s disease
and even fewer will be treated with approved Alzheimer’s disease products.
“Public and professional awareness and prioritization of Alzheimer’s
Resources. “Patients and caregivers — and even physicians — across the
nation consider Alzheimer’s a natural part of aging and largely untreatable.
Coupled with the severe stigma attached to the disease and the high cost of
approved therapies, market opportunities for Alzheimer’s disease therapies in
The new Emerging Markets report entitled Alzheimer’s Disease in
finds that the Chinese Alzheimer’s disease drug market will continue to stay
untapped and underserved despite growing use of approved therapies. Huperzine
A (Chinese brands) and donepezil (Eisai’s Aricept, Chinese brands) dominated
the treatment of Alzheimer’s disease, together capturing nearly 80 percent
market share in 2007.
In spite of the continued dominance of costly therapies, including growing
use of memantine (Lundbeck’s Ebixa) — the most recently-launched and most
expensive Alzheimer’s disease therapy in
market is expected to reach a mere
limited pool of treated patients and competition from older, entrenched
“Ultimately, patients and physicians in
regions — will continue to rely heavily on more affordable and more familiar
traditional Chinese medicines, such as ginkgo leaf extracts, if
pharmacological therapy is sought at all,” added Mr. Searles.
EMERGING MARKETS REPORTS
The Ultimate Analysis of Pharmaceutical Markets in
Decision Resources is the FIRST and ONLY company to offer a syndicated
report series for high-growth emerging markets with comprehensive
disease-specific analysis. Each report assesses the commercial opportunity in
the pharmaceutical market for a disease based on population demographics,
economic development, disease epidemiology and changing physicians’ practices.
About Decision Resources
Decision Resources (http://www.DecisionResources.com) is a world leader in
market research publications, advisory services and consulting designed to
help clients shape strategy, allocate resources and master their chosen
markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources, Inc. at
All company, brand or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact: Natalia Morales Elizabeth Marshall Decision Resources Decision Resources, Inc. 781-296-2691 781-296-2563 firstname.lastname@example.org email@example.com
SOURCE Decision Resources